arsenic trioxide has been researched along with carboplatin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Karlsson, J; Påhlman, S; Pörn-Ares, I; Øra, I | 1 |
| He, ZY; Li, DC; Li, HY; Li, SJ; Liang, ZZ; Yan, J | 1 |
1 trial(s) available for arsenic trioxide and carboplatin
| Article | Year |
|---|---|
A prospective trial to evaluate the clinical efficacy and safety of neoadjuvant chemotherapy with arsenic trioxide and carboplatin in locally advanced cervical cancer: a study protocol for randomized controlled clinical.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Platinum; Prospective Studies; Randomized Controlled Trials as Topic; Treatment Outcome; Uterine Cervical Neoplasms | 2022 |
1 other study(ies) available for arsenic trioxide and carboplatin
| Article | Year |
|---|---|
Arsenic trioxide-induced death of neuroblastoma cells involves activation of Bax and does not require p53.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Blotting, Western; Calpain; Carboplatin; Caspase 3; Caspases; Cell Line, Tumor; Cytochromes c; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Mutation; Neuroblastoma; Oxides; Proto-Oncogene Proteins c-bcl-2; Time Factors; Tumor Suppressor Protein p53; Vincristine | 2004 |